Skip to main content

Breast Cancer

Ausgabe 4/2023

Inhalt (19 Artikel)

Open Access Special Article

Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition

Tsunehisa Nomura, Masaaki Kawai, Yuna Fukuma, Yoshikazu Koike, Shinji Ozaki, Motoki Iwasaki, Seiichiro Yamamoto, Kiyoshi Takamatsu, Hitoshi Okamura, Masami Arai, Shoichiro Ootani, Hiroji Iwata, Shigehira Saji

Review Article

Efficacy and safety of surgical energy devices for axillary node dissection: a systematic review and network meta-analysis

Jun Watanabe, Yuki Kataoka, Akira Koike, Atsushi Miki, Mikio Shiozawa, Masako Sakuragi, Michiko Harao, Joji Kitayama, Naohiro Sata

Original Article

Validity of computed mean compressed fibroglandular tissue thickness and breast composition for stratification of masking risk in Japanese women

Mikinao Oiwa, Namiko Suda, Takako Morita, Yuko Takahashi, Yasuyuki Sato, Takako Hayashi, Aya Kato, Rieko Nishimura, Shu Ichihara, Tokiko Endo

Original Article

Cell-free biomimetic polyurethane-based scaffold for breast reconstruction following non-malignant lesion resection. A first-in-human study

Maria Donatella Mariniello, Matteo Ghilli, Benedetta Favati, Irini Gerges, Livio Colizzi, Margherita Tamplenizza, Alessandro Tocchio, Federico Martello, Maria Ghilardi, Maria Cristina Cossu, Serena Danti, Manuela Roncella

Original Article

Development and implementation of a decision aid for post-mastectomy breast reconstruction for Japanese women with breast cancer: a field-testing study

Yoshihiro Sowa, Naoki Inafuku, Itaru Tsuge, Hiroki Yamanaka, Motoki Katsube, Michiharu Sakamoto, Ichiro Nakayama, Naoki Morimoto

Original Article

Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients

Masayuki Nagahashi, YiWei Ling, Chie Toshikawa, Tetsu Hayashida, Yuko Kitagawa, Manabu Futamura, Takashi Kuwayama, Seigo Nakamura, Hideko Yamauchi, Teruo Yamauchi, Koji Kaneko, Chizuko Kanbayashi, Nobuaki Sato, Junko Tsuchida, Kazuki Moro, Masato Nakajima, Yoshifumi Shimada, Hiroshi Ichikawa, Stephen Lyle, Yasuo Miyoshi, Kazuaki Takabe, Shujiro Okuda, Toshifumi Wakai

Open Access Original Article

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer Jr, Andrew Tutt

Open Access Correction

Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer Jr, Andrew Tutt

Open Access Original Article

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry

Shozo Ohsumi, Kenichi Watanabe, Naoto Kondo, Yoshimasa Kosaka, Takashi Ishikawa, Miyuki Kitahara, Shinichiro Kubo, Mari S. Oba, Tetsuya Kimura, Atsushi Takita, Hirofumi Mukai

Open Access Original Article

Increased breast cancer mortality due to treatment delay and needle biopsy type: a retrospective analysis of SEER-medicare

Rashmi Pathak, Macall Leslie, Priya Dondapati, Rachel Davis, Kenichi Tanaka, Elizabeth Jett, Inna Chervoneva, Takemi Tanaka

Original Article

High-accuracy prediction of axillary lymph node metastasis in invasive lobular carcinoma using focal cortical thickening on magnetic resonance imaging

Shun Kawaguchi, Keiichi Kinowaki, Nobuko Tamura, Tomohiko Masumoto, Aya Nishikawa, Akio Shibata, Kiyo Tanaka, Yoko Kobayashi, Takuya Ogura, Junichiro Sato, Hidetaka Kawabata

Open Access Original Article

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan

K. Nozawa, M. Terada, M. Onishi, Y. Ozaki, T. Takano, W. Fakhouri, D. Novick, J. M. Haro, L. H. Faris, T. Kawaguchi, Y. Tanizawa, Junji Tsurutani

Open Access Original Article

Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation

Leilei Li, Wenhui Yang, Daqi Jia, Shiqi Zheng, Yuzhe Gao, Guanghui Wang

Rapid Communication

The effect of combined risk factors on breast cancer-related lymphedema: a study using decision trees

Kazumi Jinbo, Takaaki Fujita, Ryuichi Kasahara, Ryohei Jinbo, Sayaka Kisara, Jun Onobe, Izo Kimijima, Mitsuhiko Yasuda, Yuichi Yamamoto

Open Access Correction

Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region

Nobumoto Tomioka, Kanako C. Hatanaka, Dai Okuyama, Ken-ichi Watanabe, Mitsugu Yamamoto, Hideki Maeda, Hanae Tachikawa, Sayuri Kuwahara, Ai Shimizu, Hiroaki Suzuki, Yutaka Hatanaka, Masato Takahashi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.